

AMENDED CLAIMS

[received by the International Bureau on 12 January 1998 (12.01.98);
original claim 1 amended; original claims 23 and 24 cancelled;
new claim 29 added; remaining claims unchanged (3 pages)]

1. Use of a human cytomegalovirus (HCMV) protein in the preparation of a medicament for preventing or retarding the development of atherosclerotic lesions or restenosis in a mammal, wherein said medicament is administered to the mammal in an amount inducing cell mediated immunity and/or antibody response to HCMV in the mammal.
2. Use according to claim 1 wherein said HCMV protein is selected from the group consisting of HCMV proteins pp65, IE, IE-exon-4, pp150, gB, gH, pp28, and pp52.
3. Use according to claim 1 or 2 wherein the medicament is administered to a mammal in a low dose comprising between about 10 and about 80 mgs protein per inoculation.
4. Use of a nucleic acid sequence encoding a human cytomegalovirus (HCMV) protein or fragment thereof in the preparation of a medicament for preventing or retarding the development of atherosclerotic lesions or restenosis in a mammal, wherein said medicament is administered to a mammal in an amount inducing cell mediated immunity and/or antibody response to HCMV in the mammal
5. Use according to claim 4 wherein said medicament comprises an attenuated, live HCMV.
6. Use according to claim 4 wherein said medicament comprises an inactivated HCMV

20. Use according to claim 19 wherein said medicament comprises a recombinant vector comprising a nucleic acid sequence encoding said protein or fragment under the control of a regulatory sequence capable of directing expression of said *C. pneumoniae* protein sequence.

21. Use according to claim 20 wherein said vector is a virus selected from the group consisting of adenovirus, poxvirus, and retrovirus.

22. Use according to any of claim 19 to 21 wherein said amount is a low dose comprising of between 50 and 200 µg of DNA per inoculation.

25. A composition useful for preventing or retarding the development of atherosclerotic lesions or restenosis in a mammal comprising, in a suitable pharmaceutical carrier,

(a) an amount of an anti-microbial composition effective to reduce or eliminate *C. pneumoniae* infection; and

(b) an amount of an anti-viral composition effective to reduce or eliminate HCMV infection.

28. Use of a composition according to any of claims 25 to 27 in the preparation of a medicament for the treatment of atherosclerotic lesions or restenosis

29. Use of an immediate-early exon-4 subunit of HCMV in the preparation of a medicament for preventing or retarding the development of atherosclerotic lesions or restenosis in a mammal, wherein said medicament is administered to the mammal in an amount inducing cell mediated immunity and/or antibody response to HCMV in the mammal.

STATEMENT UNDER ARTICLE 19

Pursuant to Article 19(1), Applicant has amended the original claims and encloses replacement pages 36, 39 and 41. Claim 1 is amended to eliminate the words "or fragment thereof" in line 2. Claims 23 and 24 are cancelled. Claim 29 is added to claim the use of a specific fragment, that of the IE-exon 4 subunit of HCMV as provided on page 8, lines 33-34.

No changes to the drawings are required by these amendments. Only minor amendments need be made to the specification in view of these amendments, because the eliminated fragments and antibiotic compositions referred to in claims 1 and 23 and 24, are useful in combinations covered by several of the unamended original claims.